หน้าแรก
ค้นหา
Dr. Burke on Risk Stratification Strategies in Follicular Lymphoma
Website: https://www.onclive.com Twitter: / onclive Facebook: / onclive LinkedIn: / onclive
แสดงข้อมูลเพิ่มเติม 1
Dr. Burke on Risk Stratification Strategies in Follicular Lymphoma
John Burke, MD, lists the top findings from ASH 2017 regarding lymphoid malignancies
Dr. Batlevi on Emerging Therapies in Follicular Lymphoma
Dr. Winter Discusses Response in Follicular Lymphoma
Follicular Lymphoma: Optimizing Novel Agent Therapy
John Burke, MD, outlines the patient profile best suited for zanubrutinib in relapsed/refractory MCL
Deciding on Rituximab Versus Obinutuzumab in Follicular Lymphoma
John Burke, MD, offers opinion on how physicians should be thinking about the use of BTK inhibitors
Dr. Fowler on Different Responses to Therapy for Follicular Lymphoma
Dr. Kaplan on Frontline Treatment Options in Follicular Lymphoma
John Burke, MD, regarding gilteritinib in acute myeloid leukemia treatment
Accelerated Approval of Tazemetostat For Follicular Lymphoma
Dr. Bello on Biomarkers in Follicular Lymphoma
John Burke, MD, comments on clinical research examining gilteritinib in newly diagnosed AML
John Burke, MD, elaborates on the Beat AML umbrella study
Prof. Nathan Fowler | ASH 2017 | Highlights of ASH 2017 in Follicular Lymphoma
Important translocations in lymphomas and leukemias- MEDICAL STUDENTS MUST KNOW
The DOUBLE HIT LYMPHOMA (DHL) debate